Keith Murphy

Prior to founding Viscient, Mr. Murphy co-founded Organovo, the world's premier 3D bioprinting company of which he is the former CEO and Chairman Emeritus, in 2007, and led all company operations until 2017. He co-invented the NovoGen MMX bioprinter platform (named one of TIME magazine’s “Best inventions of 2010”) and grew Organovo through early investments and corporate partnerships, including major alliances with Astellas and Merck. Organovo received a number of accolades including being named one of the Most Innovative companies of the year in 2012 by MIT Technology Review and 2015 by Fast Company and Most Audacious companies in 2013 by Inc. Magazine. Organovo went public and commenced trading on the NYSE in 2013 and NASDAQ in 2016. Organovo has since focused on the development of three-dimensional liver, kidney, and cancer tissues. The most advanced program, liver tissue, has grown to encompass a range of applications from commercial use for pharmaceutical toxicology prediction to the preclinical development of human 3D liver patches for transplant patients. Prior to co-founding Organovo, Mr. Murphy spent ten years at Amgen in roles of increasing responsibility, including four years as the Global Operations Leader of denosumab, now marketed as Prolia & Xgeva ($3B+ annual sales). He holds a B.S. in Chemical Engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management. Mr. Murphy serves on the Board of the California Life Sciences Association and Adgero Biopharmaceuticals.